Patients with higher expressions of FBXL3 and FBXO3 presented a markedly prolonged survival in this study, illustrating that both of the two core FBGs could serve as biomarkers of immunotherapy for patients with ccRCC. Here, FBXL3 is linked to nonpapillary renal cell carcinoma.